Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.54 |
| ▸ | MAPT | P10636 | 4/20 | 0.54 |
| ▸ | HPGD | P15428 | 4/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | GMNN | O75496 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | BLM | P54132 | 2/20 | 0.54 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.54 |
| ▸ | CMKLR1 | Q99788 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8396440 | 0.83 | PTPN1 (0.61) | NPC1LMNAPTPN1ALDH1A1MAPT | |
| SCHEMBL14381007 | 0.82 | LMNA (0.44) | NPC1LMNAPTPN1ALDH1A1MAPT | |
| SCHEMBL4828397 | 0.82 | LMNA (0.44) | NPC1LMNAPTPN1ALDH1A1MAPT | |
| SCHEMBL27832230 | 0.81 | NPC1 (0.77) | NPC1LMNAPTPN1ALDH1A1MAPT | |
| SCHEMBL4835943 | 0.81 | LMNA (0.51) | NPC1LMNAPTPN1ALDH1A1HPGD | |
| SCHEMBL4831696 | 0.80 | HPGD (0.52) | NPC1LMNAALDH1A1MAPTHPGD | |
| SCHEMBL6514656 | 0.79 | NPC1 (0.55) | NPC1LMNAPTPN1ALDH1A1MAPT | |
| SCHEMBL14440784 | 0.79 | HRH3 (0.58) | PTPN1ALDH1A1MAPTHPGDKDM4E | |
| SCHEMBL19339818 | 0.78 | LMNA (0.55) | LMNAALDH1A1MAPTHPGDKDM4E | |
| SCHEMBL14065383 | 0.78 | LMNA (0.55) | NPC1LMNAALDH1A1MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8378116-B2 | Phenylnaphthylimidazole compound and usage of the same | SHIKOKU CHEMICALS CORPORATION (JP) | 2013-02-19 | — | — | US | disclosed |
| EP-1753728-B1 | PHENYLNAPHTHYLIMIDAZOLES FOR USE ON COPPER SURFACES DURING SOLDERING | SHIKOKU CHEM (JP) | 2012-12-19 | — | — | EP | disclosed |
| US-20120199385-A1 | PHENYLNAPHTHYLIMIDAZOLE COMPOUND AND USAGE OF THE SAME | SHIKOKU CHEMICALS CORPORATION (JP) | 2012-08-09 | — | — | US | disclosed |
| US-8183386-B2 | Phenylnaphthylimidazole compound and usage of the same | SHIKOKU CHEMICALS CORPORATION (JP) | 2012-05-22 | — | — | US | disclosed |
| US-7429607-B2 | 5-HT2B receptor antagonists | ASTERAND UK LIMITED (GB) | 2008-09-30 | — | — | US | disclosed |
| US-7429607-B2 | 5-HT2B receptor antagonists | ASTERAND UK LIMITED (GB) | 2008-09-30 | — | — | US | disclosed |
| US-7429607-B2 | 5-HT2B receptor antagonists | ASTERAND UK LIMITED (GB) | 2008-09-30 | — | — | US | disclosed |
| EP-1474140-B1 | 2-OXAZOLAMINES AND THEIR USE AS 5-HT2B RECEPTOR ANTAGONISTS | ASTERAND UK LTD (GB) | 2007-11-21 | — | — | EP | disclosed |
| EP-1474140-B1 | 2-OXAZOLAMINES AND THEIR USE AS 5-HT2B RECEPTOR ANTAGONISTS | ASTERAND UK LTD (GB) | 2007-11-21 | — | — | EP | disclosed |
| US-20070246134-A1 | Phenylnaphthylimidazole Compound and Usage of the Same | SHIKOKU CHEMICALS CORPORATION (JP) | 2007-10-25 | — | — | US | disclosed |
| EP-1753728-A1 | PHENYLNAPHTHYLIMIDAZOLES FOR USE ON COPPER SURFACES DURING SOLDERING | SHIKOKU CHEMICALS CORPORATION (JP) | 2007-02-21 | — | — | EP | disclosed |
| WO-2005121101-A1 | PHENYLNAPHTHYLIMIDAZOLES FOR USE ON COPPER SURFACES DURING SOLDERING | SHIKOKU CHEMICALS CORPORATION (JP) | 2005-12-22 | — | — | WO | disclosed |
| US-20050176791-A1 | 5-HT2B receptor antagonists | ASTERAND UK LIMITED (GB) | 2005-08-11 | — | — | US | disclosed |
| EP-1474140-A1 | 2-OXAZOLAMINES AND THEIR USE AS 5-HT2B RECEPTOR ANTAGONISTS | Pharmagene Laboratories Ltd (GB) | 2004-11-10 | — | — | EP | disclosed |
| US-20040010022-A1 | 5-HT2B receptor antagonists | ASTERAND, INC. | 2004-01-15 | — | — | US | disclosed |
| WO-2003068226-A1 | 2-OXAZOLAMINES AND THEIR USE AS 5-HT2B RECEPTOR ANTAGONISTS | PHARMAGENE LABORATORIES LIMITED (GB) | 2003-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070246134-A1 | Phenylnaphthylimidazole Compound and Usage of the Same | CYP1A1, CYP1A2, P4HA1 | NPC1 854/4885LMNA 4053/4885PTPN1 1415/4885 |
| US-20050176791-A1 | 5-HT2B receptor antagonists | HTR2B, HTR1B, HTR3B | NPC1 2500/4885LMNA 4134/4885PTPN1 1621/4885 |
| US-20040010022-A1 | 5-HT2B receptor antagonists | HTR2B, HTR1B, HTR2C | NPC1 1529/4885LMNA 3528/4885PTPN1 2159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.